Exelixis Up On Positive Phase 3 Study Results

July 15, 2014 12:48 AM

3 0

Exelixis Up On Positive Phase 3 Study Results

Exelixis’s drug Cobimetinib showed positive topline results from a phase 3 study when combined with Vemurafenib

Exelixis, Inc. (EXEL) reported positive top line results from the coBRIM study in which the company’s drug Cobimetinib was used in combination with Vemurafenib for treating patients with BRAF V600 Mutation-Positive Advanced Melanoma.

Also read: Court: Firms have duty to protect households from asbestos

Read more

To category page

Loading...